Topiramate is a recently licensed and marketed antiepileptic drug in the UK for use as add-on therapy for refractory partial epilepsy. It has multiple modes of action involving voltage-dependent sodium channels, GABA receptors and glutamate receptors. Topiramate has very favourable pharmacokinetics as it is primarily excreted unchanged. Its metabolism is, however, increased by enzyme inducers, and it can inhibit the metabolism of phenytoin in some patients. Its efficacy as adjunctive treatment in refractory partial epilepsy in adults appears good, over 40% of patients have a 50% or greater reduction in seizure frequency when topiramate is added to their regime with up to 7% becoming seizure free. The main adverse events are ataxia, impaired concentration, confusion, dizziness, fatigue, parasthesia, somnolence and 'thinking abnormal'. Most of these occurred during rapid titration. During long-term treatment, weight loss also occurred and nephrolithiasis occurred in 1.5% of patients receiving topiramate. Topiramate is a useful and well-tolerated addition to our treatment of refractory epilepsy, but it should be titrated slowly in order to avoid adverse events.
INTRODUCTION
There are two main reasons for new antiepileptic drug (AED) development: (1) to develop AEDs for use in patients with epilepsy resistant to available AEDs and (2) to develop AEDs with better side-effect and pharmacokinetic profiles than currently available AEDs. Approximately 20% of patients with epilepsy are resistant to therapy with first line AED treatment and only the minority of these patients are amenable to epilepsy surgery'. The effect of new AEDs on the prognosis of this population group has been disappointing, and new, more effective AEDs are still required2. Topiramate is a recently licensed and marketed (October 1995) AED in the UK for use as add-on therapy for partial seizures with or without secondarily generalized seizures in patients inadequately controlled on conventional first line antiepileptic treatment. Despite its recent marketing, there is still a dearth of information on topiramate in peer-reviewed journals and thus unfortunately much of the information on the drug has been gleaned from personal knowledge, abstracts and product monographs.
MECHANISM
OF ACTION Topiramate (2,3;4,5-bis-O-(l-methylidene)-beta-D-fractopyranose sulphamate) is a sulphamatesubstituted monosaccharide which exhibits some inhibition of carbonic anhydrase, but whose action is likely to be independent of this effect. Acetazolamide-tolerant mice are not tolerant to topiramate, implying that these AEDs act by different mechanisms3. It is effective against maximal electroshock, but not chemicallyinduced seizures in rats, and thus in animal models has a similar spectrum of activity to phenytoin3. Topiramate appears to have multiple modes of action. It acts at voltage-dependent sodium channels blocking the spread of seizures4, it enhances GABAA evoked chloride currents at a non-benzodiazepine receptor site' and it antagonises AMPA subtype glutamate receptors6. The role of this latter mechanism is still unclear.
PHARMACOKINETICS
In healthy volunteers, topiramate is well absorbed following oral ingestion with a time to maximum concentration of 2-4 hours'. The rate of absorption may be slowed by food, but the extent of absorption remains unchanged'. It has minimal binding to plasma proteins (15%). It has linear and predictable pharmacokinetics, and it is predominantly excreted unchanged in the urine with an elimination half-life of 19-23 hours'. Topiramate does however undergo some metabolism and the plasma concentrations and halflife of topiramate are reduced by phenytoin, and carbamazepine"'.
Topiramate should thus be taken at least twice daily.
Topiramate has no effect on the plasma concentrations of carbarnazepine'O. There is some evidence that the area under the concentration vs. time curve for phenytoin is greater with coadministration of topiramate in a few patients". This interaction is possibly due to topiramate inhibiting the uncommon CYP2C19 isoform of cytochrome P45013. This isoform has other substrates such as diazepam and omeprazole, and thus topiramate could inhibit the metabolism of these". However, topiramate does not inhibit any other CYP450 isoforms and thus would be expected to have very few inhibition based drug interactionsX3. In patients with epilepsy, there appears to be no clinically significant interaction between valproic acid and topiramate14. However, topiramate does induce a significant change in the valproate metabolic profile, a fall in glucuronide conjugates was accompanied by a small increase in oxidative metabolites of valproate15. The significance of this is unknown. There is an interaction with the contraceptive pill; contraceptive pills containing at least 50 pg of oestrogen should be used6. There is no correlation between plasma concentrations and either median percent reduction in seizure rates or percentage responders16. Statistically significant increases in mean plasma concentrations occurred in patients experiencing weight loss and anorexia, and there was a trend towards higher plasma concentrations for those experiencing adverse events16. Thus overall topiramate has favourable pharmacokinetics, which compare well with recently licensed AEDs, and AEDs presently still under development".
EFFICACY IN HUMANS
Preliminary results from trials suggest that topiramate is useful in partial seizures and in patients with Lennox-Gastaut syndrome '8-22 . In these trials doses of up to 1800 mg/day were well tolerated, and in the USA trials are underway with doses as high as 48OOmgldap.
Five double-blind, placebo-controlled, randomized trials of topiramate (200-1000 mg) as add-on in refractory partial epilepsy (total of 534 patients) have been carried out in the US and Europe24. Topiramate produced a significant reduction in secondarily generalized, complex partial and simple partial seizure rates. Significantly more patients (19%) on topiramate than placebo had a 75% reduction in seizures, and significantly more became seizure free (4%)*". This last figure compares well with a meta-analysis of other new drugs in which less than 2% of patients became seizure free*. Responder rates (patients with a 50% or greater reduction in seizures) in the European double blind studies were 35% for 400 mg/day, 47% for 600 mg/daJ6 and 43% for 800 mg/daf'.
In this last trial 7% became seizure free*'. In a novel trial design, topiramate low dose (100 mg/day) was compared with topiramate high dose (1000 mg/day) in a double-blind fashion in patients with refractory epilepsy who had had their concomitant AEDs withdrawn=. This trial lasted 112 days, but patients were withdrawn from the trial if they met any of a set of criteria that were used to determine if seizure control had deteriorated from baseline. Overall, time to withdrawal was longer for those taking 1000 mg/day topiramate and significantly more of this group completed the trialz.
TOLERABILITY AND SAFETY
There has been over 2000-person years of experience with topiramate and it appears to be well tolerated6. Overall in the double blind studies ataxia, impaired concentration, confusion, dizziness, fatigue, parasthesia, somnolence and 'thinking abnormal' occurred in 5% or more patients6. Over 80% of patients who experienced adverse events during titration did not continue to report these events by the fourth month6. Thus many of these adverse events may have been due to the rapid (3-6 week) titration that occurred during these trials. During long-term treatment weight loss also occurred, this happened in the first three months of treatment and peaked by 12-15 months of treatment6.
Nephrolithiasis occurred in 1.5% of patients treated with topiramate; the annual incidence is similar to that of nephrolithiasis caused by acetazolamide*'.
In cases where analysis was performed the stones were primarily calcium phosphate stones. The mechanism of action of nephrolithiasis caused by topiramate is likely to be related to decreased citrate excretion3'. So far no other serious idiosyncratic reactions to topiramate have been identified.
Teratogenic effects of topiramate have been noted in animal models and are similar to those observed with acetazolamide. They mainly consist of skeletal malformations including: rightsided ectrodactyl and rib and vertebral malformations in rabbit@.
The total withdrawal rate due to adverse events in the double-blind studies was approximately 14% with the majority of these withdrawals occurring during the titration phase". This figure is higher than that seen in the double-blind trials of gabapentin, vigabatrin and lamotrigine31, and it may be related to the titration rate of topiramate being too rapid, although this requires further investigation.
Carbonic anhydrase inhibitors can produce gastric hyperplasia, by decreasing gastric acid secretion and consequently causing increased gastrin levels. Topiramate, however, did not have significant gastrointestinal adverse events6 and furthermore an endoscopic study in eight patients on long-term topiramate treatment (3 years) demonstrated no effect of topiramate on gastric levels or gastric mucosal histology*.
Topiramate has also been used in children and has been found to be safe, well-tolerated and easy to titrate33. In one paediatric trial, topiramate was introduced at a dose of 1 mg/kg/day for the first week increasing to 3mg/kg/day for the second week, 6 mg/kg/day for the third week and then finally 9 mg/kg/day for the fourth week33.
CLINICAL USE
Topiramate is available in 25 mg, 50 mg, 100 mg and 200 mg tablets. The minimal effective dose appears to be 200 mg and most patients will need 200-6OOmg/day in divided doses. During the trials, withdrawals and adverse events may have been due to rapid titration of topiramate, and it should thus be titrated slowly. The recommended starting dose is lOOmg/day in divided doses increasing after one week to 2OOmg/day in divided doses. Thereafter the dose can be increased by 200 mg/day increments weekly up to a maximum dose of 8OOmg/day. Some patients require an even slower titration, and certainly those patients who are not taking an enzyme inducer could benefit from an initial starting dose of 25-50 mg/day increasing by 25-50 mg/day increments weekly up to 200 mg/day in divided doses. Thereafter increments of 100 mg/day weekly should be used up to a maximum dose of 8OOmg/day.
Patients with renal impairment require a slower titration (2 weekly increments) and will generally require lower doses". Hepatic impairment has only a minimal effect on topiramate kinetics, as does age6. Patients on phenytoin should have their phenytoin plasma concentrations monitored.
Withdrawal of topiramate should occur by lOOmg/day weekly, although faster withdrawal rates have been tolerated.
CONCLUSION
Topiramate is a new AED with a novel mechanism of action and favourable pharmacokinetics. Its tested efficacy as adjunctive treatment in refractory partial epilepsy in clinical trials compares with other new AEDs. There have also been reports of its effectiveness in LennoxGastaut and other epilepsy syndromes, although the results of trials in these patient groups are awaited. Topiramate predominantly has CNS side-effects that are common to most AEDs, and these adverse events usually occurred during rapid titration. During double-blind trial, withdrawal rates due to adverse events appeared to be slightly greater than that seen with other new AEDs, but again this may be related to rapid titration. Renal stones occurred in approximately 1.5% of patients (i.e. with a similar frequency in acetazolamide). Topiramate appears to be an effective and well-tolerated addition to our range of AEDs. However, as with all new AEDs, a number of caveats need to be made. The first is that the development of tolerance and some long-term side-effects may not be evident because of the time limit imposed on AED trials. The second is that the total number of patients included in AED trials is relatively small, and thus rare but clinically important side-effects like, for example, aplastic anaemia may be missed (as occurred with the new AED felbamate). Thirdly, new AED trials exclude pregnant patients or those on inadequate contraception, and thus there are scarce data on the safety of new AEDs during pregnancy and on the developing foetus. Lastly, drug trials are performed in selected population and the drug could have a different side-effect and tolerability profile in different population groups. These problems emphasise the importance of case reporting and notification in early and even late post-marketing phases. The eventual role of topiramate (as, indeed, most new AEDs) in the treatment of epilepsy remains to be determined, and only clinical experience over many years will answer this question. Topiramate does, however, appear to be a useful addition to the treatment of refractory epilepsy. 
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